Post

New research · Urology
Pathology · 2d
StudyPathology · 2026

Performance assessment of five Legionella urinary antigen tests for Legionella pneumophila and Legionellalongbeachae.

Francesca Azzato, Leandra Elieh, Rianne Brizuela … Maryza Graham
Read paper
UrologyStudy

ImmuView test accurately detects Legionella longbeachae in urine samples.

Performance assessment of five Legionella urinary antigen tests for Legionella pneumophila and Legionellalongbeachae.

Francesca Azzato et al. · Pathology · 2026
Background

In parts of Asia and the Western Pacific, Legionella longbeachae is also a common cause.

Results
sensitivity and specificity for L. longbeachae
The ImmuView test correctly identified all L. longbeachae infections and those without it
More results

Legionnaires' disease (LD) is a severe pneumonia caused by Legionella species., with Legionella pneumophila serogroup 1 (SG1) responsible for 70-80% of cases in Europe and the United States.

Most urinary antigen tests (UATs) target only L. pneumophila SG1, limiting detection of other species.

More results

A total of 81 urine samples were tested across all assays, except STANDARD F (n=80).

“
Conclusion · 1 of 2

In regions where L. longbeachae represents a substantial proportion of Legionella infections, the ImmuView assay offers an effective primary screening approach since it can simultaneously detect both L. pneumophila SG1 and L.

Conclusion · 2 of 2

longbeachae in a single test, thereby minimising reliance on slower diagnostic methods such as culture or PCR.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Review
31.0 months
Combination therapy meant a longer time before the cancer got worse
Cohort Study
98%
98% of patients had no significant rectocele after laparoscopic double sacrocolpopexy.
Cohort Study
OR 0.10
Beyond 4000 J/ml, the odds of reintervention are 90% lower.
Cohort Study
SIR 1.67
young bladder cancer survivors have a higher risk of developing second cancers compared to the general population
Randomized Trial
HR 0·55
adding SBRT to systemic therapy lowered the risk of death